Similarly, different molecular subtypes of breast cancer defined by gene expression profiling respond differently to preoperative chemotherapy, with basal-like and HER2-positive subtypes being more sensitive to paclitaxel and doxorubicin than luminal and normal-like cancers [136]. This evidence concerns the gene ERBB2 and breast carcinoma.